Abstract:Background The E2F family of transcription factors play a crucial role in the development of various cancers. However, E2F members lack targetable binding pockets and are typically considered "undruggable". Unlike canonical small-molecule therapeutics, molecular glues mediate new E3 ligase-protein interactions to induce selective proteasomal degradation, which represents an attractive option to overcome these limitations.Methods Human proteome microarray was utilized to identify a natural product-derived molecular glue for targeting E2F2 degradation. Co-IP analysis with stable isotope labeling of amino acids in cell culture (SILAC)-based quantitative proteomics was carried out to further explore the E3 ligase for E2F2 degradation.Findings In this study, we identified a molecular glue bufalin, which significantly promoted E2F2 degradation. Unexpectedly, E2F2 underwent ubiquitination and proteasomal degradation via a previously undisclosed atypical E3 ligase, zinc finger protein 91 (ZFP91). In particular, we observed that bufalin markedly promoted E2F2-ZFP91 complex formation, thereby leading to E2F2 polyubiquitination via K48-linked ubiquitin chains for degradation. E2F2 degradation subsequently caused transcriptional suppression of multiple oncogenes including c-Myc, CCNE1, CCNE2, MCM5 and CDK1, and inhibited hepatocellular carcinoma growth in vitro and in vivo.Interpretation Collectively, our findings open up a new direction for transcription factors degradation by targeting atypical E3 ligase ZFP91. Meanwhile, the chemical knockdown strategy with molecular glue may promote innovative transcription factor degrader development in cancer therapy.Funding This work was financially supported by the National Key Research and Development Project of China (2022YFC3501601), National Natural Sciences Foundation of China (81973505, 82174008, 82030114), and China Postdoctoral Science Foundation (2019M650396), the Fundamental Research Funds for the Central Universities.Copyright (c) 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

P53 upregulation by USP7-engaging molecular glues

Generation and Validation of Intracellular Ubiquitin Variant Inhibitors for USP7 and USP10.

Small Molecule Inhibitors of the P53-Mdm2

Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?

Glutathionylation-dependent proteasomal degradation of wide-spectrum mutant p53 proteins by engineered zeolitic imidazolate framework-8

An Overview of the Deubiquitinase USP53: A Promising Diagnostic Marker and Therapeutic Target

Inhibition of USP14 Deubiquitinating Activity As a Potential Therapy for Tumors with P53 Deficiency

Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy

Treatment with B-Ap15 to Inhibit UCHL5 and USP14 Deubiquitinating Activity and Enhance P27 and Cyclin E1 for Tumors with P53 Deficiency

Charged Molecular Glue Discovery Enabled by Targeted Degron Display

In silico screening and computational evaluation of novel promising USP14 inhibitors targeting the palm-thumb pocket

Molecular glue-mediated targeted protein degradation: A novel strategy in small-molecule drug development

Molecular glue triggers degradation of PHGDH by enhancing the interaction between DDB1 and PHGDH

Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction

Targeting the Apoptotic Mcl-1-PUMA Interface with a Dual-Acting Compound

Identification of new leads against ubiquitin specific protease-7 (USP7): a step towards the potential treatment of cancers

Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex

Atypical E3 Ligase ZFP91 Promotes Small-Molecule-induced E2F2 Transcription Factor Degradation for Cancer Therapy

Structure-based Virtual Screening of Novel USP5 Inhibitors Targeting the Zinc Finger Ubiquitin-Binding Domain

Acetylation-dependent deubiquitinase USP26 stabilizes BAG3 to promote breast cancer progression

Gardenin B, a Natural Inhibitor for USP7: in Vitro Evaluation and in Silico Identification